Orally Delivered CRISPR Therapy, Groundbreaking Evolution
/in CRISPR, Not PCa related, Preclinical Research/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/in Preclinical Research/by MaxNext-Generation ADCs for Cancer Treatment with Potential in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 16/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! I hope this collection of very promising clinical and preclinical research makes a nice Easter gift for you. Wishing you all a warm hug and a Happy Easter! Stay strong and fight on! As usual, we also have a podcast if […]
Phase1/2: Kesonotide For Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1 Trial: GEN1057 Bispecific-Antibody In Metastatic Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxCD-001: A Promising Novel Dual-Targeting Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxSDV2102: A Promising ADC That Targets PSMA Expressing Tumors
/in Antibody-Drug Conjugate, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- New PSMA Radiohybrid Combines PET Imaging With Alpha Therapy October 14, 2026
- Phase 2 Trial Tests Tinengotinib With Darolutamide or Enzalutamide in Hormone-Resistant Prostate Cancer October 13, 2026
- Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance October 13, 2026
- Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer October 13, 2026